Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (199)	8/20/2001 10:54:25 AM
From: keokalani'nui	Read Replies (1) \| Respond to of 625

Well, there is this. But I don't much care for companies that crow about a dismissal on venue. MorphoSys Wins Second Motion to Dismiss on CAT Winter II Patent Suit in San Diego Court MARTINSRIED and MUNICH, Germany, Aug. 20 /PRNewswire/ -- MorphoSys AG (Neuer Markt: MOR), the German biotechnology company, announced today that a court in San Diego has granted its motion to dismiss a second attempt by Cambridge Antibody Technology Ltd. (CAT), together with The Medical Research Council, The Scripps Research Institute and Stratagene to bring a suit alleging infringement of their ``Winter II'' US patent (No. 6,248,516). In late June, the Court dismissed CAT's earlier-filed suit against MorphoSys on the same patent. Prior to CAT's second filing, MorphoSys filed a suit in a District Court in Washington, DC seeking a declaration of non-infringement and invalidity of the Winter II patent. ``We are very happy with this decision'', stated Dr. Thomas von Rueden, Chief Scientific Officer, MorphoSys AG. ``Our view that there was no basis for CAT to bring this suit in San Diego has been conclusively upheld.''